Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs MYLAN (US) - Comparison Results

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 AUROBINDO PHARMA   MYLAN
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-23
MYLAN
Dec-18
AUROBINDO PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs7153,978-   
Low Rs3972,190-   
Sales per share (Unadj.) Rs424.21,830.6-  
Earnings per share (Unadj.) Rs32.949.7-  
Cash flow per share (Unadj.) Rs54.1392.5-  
Dividends per share (Unadj.) Rs3.000-  
Avg Dividend yield %0.50-  
Book value per share (Unadj.) Rs458.11,980.4-  
Shares outstanding (eoy) m585.94514.50-   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x1.31.7 77.8%   
Avg P/E ratio x16.962.0 27.2%  
P/CF ratio (eoy) x10.37.9 130.7%  
Price / Book Value ratio x1.21.6 77.9%  
Dividend payout %9.10-   
Avg Mkt Cap Rs m325,7531,586,770 20.5%   
No. of employees `000NA35.0 0.0%   
Total wages/salary Rs m35,2230-   
Avg. sales/employee Rs Th026,910.4-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th0730.7-  
INCOME DATA
Net Sales Rs m248,554941,863 26.4%  
Other income Rs m2,9060-   
Total revenues Rs m251,460941,863 26.7%   
Gross profit Rs m37,070243,719 15.2%  
Depreciation Rs m12,446176,354 7.1%   
Interest Rs m1,40545,300 3.1%   
Profit before tax Rs m26,12522,065 118.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6,849-3,510 -195.1%   
Profit after tax Rs m19,27725,575 75.4%  
Gross profit margin %14.925.9 57.6%  
Effective tax rate %26.2-15.9 -164.8%   
Net profit margin %7.82.7 285.6%  
BALANCE SHEET DATA
Current assets Rs m214,599525,936 40.8%   
Current liabilities Rs m114,938383,465 30.0%   
Net working cap to sales %40.115.1 265.1%  
Current ratio x1.91.4 136.1%  
Inventory Days Days2184 24.7%  
Debtors Days Days6693 70.3%  
Net fixed assets Rs m176,668182,706 96.7%   
Share capital Rs m586501 116.8%   
"Free" reserves Rs m267,8130-   
Net worth Rs m268,3991,018,924 26.3%   
Long term debt Rs m6,1901,099,746 0.6%   
Total assets Rs m392,1252,733,150 14.3%  
Interest coverage x19.61.5 1,317.8%   
Debt to equity ratio x01.1 2.1%  
Sales to assets ratio x0.60.3 183.9%   
Return on assets %5.32.6 203.4%  
Return on equity %7.22.5 286.1%  
Return on capital %10.03.2 315.3%  
Exports to sales %33.70-   
Imports to sales %15.30-   
Net fx Rs m44,0360-   
CASH FLOW
From Operations Rs m23,868195,719 12.2%  
From Investments Rs m-39,778-101,165 39.3%  
From Financial Activity Rs m18,144-91,177 -19.9%  
Net Cashflow Rs m2,2981,621 141.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 83.58 Rs / USD

Compare AUROBINDO PHARMA With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare AUROBINDO PHARMA With: AJANTA PHARMA  SUVEN PHARMACEUTICALS  PIRAMAL PHARMA  SEQUENT SCIENTIFIC  BH.IMMUN&BIO  



Today's Market

Sensex Today Rallies 599 Points | Private Banks Rally | 4 Reasons Why Indian Share Market is Rising Sensex Today Rallies 599 Points | Private Banks Rally | 4 Reasons Why Indian Share Market is Rising(Closing)

After opening the day deep in red, Indian share markets reversed the trend as the session progressed and ended on firm footing.